Drug intelligence / Profile preview

Jifafang

Development stage: Preclinical
Lead developer: Guizhou University of Traditional Chinese Medicine

Overview

Jifafang is a Traditional Chinese Medicine (TCM) formula currently undergoing clinical investigation for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). It is designed to be administered alongside conventional Western medicine treatments, which typically include oxygen therapy, antibiotics, bronchodilators, expectorants, hormones, and noninvasive ventilation. The drug's development is being led by Chinese institutions specializing in traditional medicine, suggesting its composition is likely based on herbal ingredients and traditional TCM principles for managing respiratory conditions.

Beyond the preview

Go deeper on Jifafang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jifafang.

Explore the full profile